Breaking News | Fondaparinux Sodium API Gains Marketing Authorization!
Release Date:2026-10-08 11:33:27 Views:375
Newland Pharma has recently received approval from the National Medical Products Administration (NMPA) for its Fondaparinux Sodium API. This marks a significant milestone in the company's development of anticoagulant APIs and further expands its product portfolio into the anticoagulant therapeutic area. It also provides our downstream formulation partners with an additional competitive and reliable sourcing option.
Overview of NMPA-Approved APIs
Through sustained investment in R&D and regulatory submissions, Newland Pharma has built a diversified API portfolio covering multiple therapeutic areas, including anti-infectives, cardiovascular and cerebrovascular diseases, anesthesia and pain management, gastrointestinal disorders, allergy treatment, iron supplementation, and anticoagulation.
The approved APIs and their primary applications are outlined below:

About Fondaparinux Sodium
Fondaparinux Sodium is a fully synthetic, selective Factor Xa inhibitor with a well-defined molecular structure and no animal-derived components. It is indicated for the prevention of venous thromboembolism (VTE) following major orthopedic surgeries, including hip fracture surgery and hip or knee replacement. It is also used in the anticoagulant treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and acute coronary syndrome (ACS).
Supporting Our Partners, Building a Better Future Together
The approval of Fondaparinux Sodium API strengthens our ability to provide downstream formulation manufacturers with a reliable supply of high-quality raw materials. It will help support the quality and accessibility of domestically manufactured anticoagulant products across various therapeutic areas, including orthopedic thromboprophylaxis, cardiovascular anticoagulation, and anticoagulation during pregnancy.